

Meeting Agenda

PROPOSALS

01

- Election of Directors
- Ratification of Independent Registered Public Accounting Firm
- Advisory Vote on Executive Compensation (“Say-on-Pay” Vote)

VOTING & VOTING RESULTS

02

COMPANY UPDATE

03

QUESTIONS & ANSWERS

04

2026 ANNUAL SHAREHOLDER MEETING

Strategy & Business Update



Leonard S. Schleifer, MD, PhD

Co-Founder, Board Co-Chair,
President & Chief Executive Officer

Note regarding forward-looking statements and non-GAAP financial measures

This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, competing drugs and product candidates that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") (including biosimilar versions of Regeneron's Products); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties or other factors beyond Regeneron's control on the commercial success of Regeneron's Products and Regeneron's Product Candidates; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and Regeneron's Product Candidates and research and clinical programs now underway or planned, including without limitation EYLEA HD[®] (afibercept) Injection 8 mg, EYLEA[®] (afibercept) Injection, Dupixent[®] (dupilumab), Libtayo[®] (cemiplimab), Praluent[®] (alirocumab), Kevzara[®] (sarilumab), Evkeeza[®] (evinacumab), Veopoz[®] (pozelimab), Ordspono[™] (dronextamab), Lynozfyc[™] (linvoseltamab), Otamendi[™] (lunsotogene parvec-cwha), other clinical programs discussed in this presentation, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of the anticipated milestones discussed or referenced in this presentation; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as those listed above; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; Regeneron's ability to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron's drug pricing strategy, including in connection with our April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; unanticipated expenses; the costs of developing, producing, and selling products; Regeneron's ability to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; Regeneron's estimates of market opportunities for Regeneron's Products and Regeneron's Product Candidates; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

This presentation includes or references non-GAAP net income per diluted share and net product sales growth on a constant currency basis for certain of Regeneron's Products, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). These and other non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. Management uses this and other non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations. However, there are limitations in the use of such non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures used in this presentation is provided on slide 22.



REGENERON[®]

The landscape of biotechnology

Breakthrough science requires an ecosystem – and that ecosystem is under pressure.



The policy environment is at an inflection point

As Washington debates drug prices and biopharma is routinely vilified, the fundamental question is overlooked: how do we properly value the innovative industry that delivers new medicines?



Global competition is intensifying

China is pairing capital with streamlined regulatory pathways to build a competing biotech sector. America's leadership – built over decades – can erode if we weaken the innovation ecosystem.



Science is powerful – but success is rare

We have made some of the most important scientific breakthroughs in history. America leads the world in drug discovery.¹ Yet 89% of drugs entering clinical trials never reach patients.¹



Time and capital requirements are immense

Drug discovery and development is a long game. It requires enormous up-front capital, decades of sustained commitment, and an environment that supports the entire chain – from basic science to clinical trials to large-scale manufacturing.



We believe America can sustain its leadership – but it requires action.

What is most critical to protect American biomedical innovation leadership?

Fix the global cost imbalance

- Other wealthy nations benefit from American innovation while contributing far less
- This has been our long-standing view, and **why we supported the Most Favored Nation initiative.**

MFN is a meaningful step, but must be paired with sustained investment in U.S. R&D

Keep regulatory pathways sharp and smart

- Clear review processes encourage long-term investment; uncertainty pushes capital elsewhere
- The goal is a modernized, well-resourced FDA that is both scientifically rigorous and operationally efficient

Invest seriously in the talent pipeline

- America must strengthen STEM education and build pathways that develop the next generation of scientists
- **We are committed to inspiring young innovators** through the Regeneron Science Talent Search, the International Science and Engineering Fair, and other engaging STEM efforts

Treat domestic manufacturing as strategic infrastructure

- Industrial readiness is not optional – it is national security policy as much as health policy
- **We have invested for years in large-scale U.S. manufacturing** capacity and advocated for increased domestic biopharmaceutical manufacturing; incentives for resilient supply chains must follow

The landscape of biotechnology

Breakthrough science requires an ecosystem – and that ecosystem is under pressure.



The policy environment is at an inflection point

As Washington debates drug prices and biopharma is routinely vilified, the fundamental question is overlooked: how do we properly value the innovative industry that delivers new medicines?



Global competition is intensifying

China is pairing capital with streamlined regulatory pathways to build a competing biotech sector. America's leadership – built over decades – can erode if we weaken the innovation ecosystem.



Science is powerful – but success is rare

We have made some of the most important scientific breakthroughs in history. America leads the world in drug discovery.¹ Yet 89% of drugs entering clinical trials never reach patients.¹



Time and capital requirements are immense

Drug discovery and development is a long game. It requires enormous up-front capital, decades of sustained commitment, and an environment that supports the entire chain – from basic science to clinical trials to large-scale manufacturing.



We know Regeneron can sustain its leadership – because we are built for this.

REGENERON

SCIENCE TO MEDICINE®



Integrate Genetics, Proteomics and Big Data

World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics



Accelerate Innovation and R&D Productivity

Powerful toolkit of proprietary, turnkey technology platforms provides enduring competitive advantages

Leaders in human antibodies

VELOC1-BI[®]
Pioneers in bispecifics

Genetics Medicines
siRNA | gene editing | AAV gene therapy

Follow the Science

~50 clinical programs across six core therapeutic areas provides a strong foundation for future growth



Deliver Breakthrough Medicines

15 internally-developed therapies have been approved, poised to deliver many more...

DUPIXENT[®]
(dupilumab)

LIBTAYO[®]
(sotrovimab)

LYNZOZYFC[®]
(lynestiprone)

EYLEA HD[®]
(aflibercept)

EYLEA[®]
(aflibercept)

**Leveraging the power of science to bring transformative medicines to patients...
over and over again**

Q1 2026 financial performance and pipeline developments



1Q26 Total Revenues

\$3.6B

1Q26 Non-GAAP EPS*

\$9.47

Notable R&D Pipeline Advancements

DUPIXENT

- FDA approved for treatment of allergic fungal rhinosinusitis in patients aged 6y+
- Approved in Japan for treatment of moderate-to-severe bullous pemphigoid
- Approved in U.S. and Europe for pediatric chronic spontaneous urticaria (age 2 -11 yrs)

EYLEA HD

- FDA approved extended dosing intervals (every-20-week dosing regimen) in wAMD and DME

Other Products and Programs

- FDA accepted BLA for **garetosmab** in FOP with Priority Review (PDUFA August 2026)
- FDA approved **Otarmeni™** (lunsotogene parvec-cwha; DB-OTO) to treat genetic hearing loss under the Commissioner's National Priority Voucher program
- Submitted NDA for **cemdisiran** in generalized myasthenia gravis utilizing a Priority Review Voucher; FDA decision expected Q4 2026
- Phase 3 study of **fianlimab + cemiplimab** in adjuvant melanoma passed first interim analysis; study continues to the next interim analysis (2H26)

Continued growth and expansion in multiple Type 2 indications

Q1 2026 Dupixent global net sales of \$4.9B (+31% YoY*)

>1.4 million patients on therapy globally

Approved in **NINE** indications globally


Chronic Spontaneous Urticaria (CSU) pediatrics approved by FDA and EC (April 2026)

Allergic Fungal Rhinosinusitis (AFRS) approved in U.S. (February 2026)

Bullous Pemphigoid (BP) EC decision expected in 2H 2026

#1 prescribed biologic among dermatologists, pulmonologists, allergists and ENTs

Dupixent global net product sales, in \$ Millions



Sanofi records global net product sales of Dupixent

Sustaining I&I leadership and unlocking new growth opportunities

Leveraging learnings from Dupixent and disease biology to advance next-gen approaches to treat inflammatory diseases


Pursuing multi-pronged approach to sustain I&I leadership into the next decade

'Next-gen' IL-4/IL-13 opportunities

- Longer **Dupixent*** dosing intervals
- **Novel long-acting IL-4Ra⁺** antibody
- Long-acting, fully-human **IL-13 & IL-4** antibodies with optimized binding properties
 - Expedited AD development plan for IL-13; FIH study initiated
- Long-acting **IL-4xIL-13 bispecific**

Investigating novel I&I targets

- **Itepekimab* (IL-33)**: Advancing in respiratory indications with strong genetic associations
 - Phase 3 CRSwNP data anticipated in 2027
- Additional **genetic-defined targets** discovered by Regeneron Genetics Center, each with pipeline-in-a-product potential, expected to enter clinic in 2026-2027



Advancing broader allergy pipeline into large commercial opportunities

Allergen-specific antibody approaches

- **Cat (FelD1)** and **birch (BetV1)** allergy programs each demonstrated positive Phase 3 results in 2025
- Registration-enabling studies initiating in 2026 for both programs; data anticipated in 2027

Severe IgE-mediated food allergy

- **Lynozytic (BCMAxCD3) + Dupixent*** achieved proof-of-principle; demonstrated sustained >90% reductions in IgE in 4 of 4 evaluable patients
- Advancing **novel therapeutic candidates** to develop more-targeted and/or specific approaches to potentially **eliminate IgE-mediated allergies**; FIH expected by 2027

EYLEA HD + EYLEA in the U.S.


EYLEA HD + EYLEA remain the U.S. branded anti-VEGF category leader

Goal to establish EYLEA HD as new standard of care for retinal diseases



- Q1 2026 U.S. net product sales of **\$468M**
- Comprised **~50%** of Q1 2026 aggregate EYLEA + EYLEA HD U.S. net product sales
- Net sales driven by increasing demand (+10% q/q)
- Approval of RVO and flexible dosing intervals expected to support demand growth in 2026
- Q1 2026 EYLEA HD sales were negatively impacted by:
 - Typical seasonality for patient reauthorizations
 - Elevated inventory of ~\$30M at the end of Q4 2025, which was absorbed in Q1 2026

U.S. Net Product Sales, in \$ Millions



Strengthening EYLEA HD's best-in-class profile

Recent label enhancements expected to broaden adoption to patients with RVO and to patients requiring more frequent dosing



Maximized Dosing Flexibility

- Offers physicians **greater flexibility** to tailor treatment for individual patient needs with approved regimens with Q4W → Q20W dosing intervals
- Best-in-class **durability** profile complemented with ability to treat patients who may require more frequent injections



Macula Edema following Retinal Vein Occlusion (RVO)

- EYLEA HD **every 8 weeks** delivered non-inferior visual gains vs. EYLEA every 4 weeks, plus flexibility for **treatment beyond 6 months**
- RVO represented **~20%** of EYLEA net sales in 2025



Pre-Filled Syringe

- Regulatory application resubmitted for Catalent Indiana
- Regulatory application for second third-party manufacturer remains pending (FDA did not act by the April 2026 PDUFA)

EYLEA HD now offers a broad indication set and the greatest dosing flexibility in the anti-VEGF category

Key growth driver and foundational to oncology portfolio

Building on leadership in non-melanoma skin cancers with adjuvant CSCC launch; building share in advanced non small cell lung cancer

Strong and consistent growth

- Q1 2026 global net sales of **\$438M (+48% YoY*)**



Advanced
NSCLC

- One of two PD-1 antibodies FDA-approved for use in combination with chemotherapy irrespective of histology or PD-L1 expression levels
- #2 most prescribed I/O treatment for advanced NSCLC in the U.S.



Advanced
BCC

- Leading anti-PD-1/L1 therapy in advanced CSCC and BCC




Advanced
CSCC

First and only immunotherapy approved for high-risk adjuvant CSCC


Global launch underway

Libtayo global net product sales,
in \$ Millions



Driving global Oncology growth through differentiated launches

Positive early launch progress with Libtayo in adjuvant CSCC and Linozyfic in r/r multiple myeloma



Otarmeni FDA Approval Marks Breakthrough in Genetic Medicine



Otarmeni is the first and only *in vivo* gene therapy for *OTOF*-related hearing loss – and it's free for eligible patients in the U.S.

- First FDA-approved gene therapy to restore a neurosensory function to normal levels
- Regeneron's first approved genetic medicine, showcasing the company's ability to advance new therapeutic approaches to address conditions with significant unmet medical need
- In the CHORD clinical trial, results showed:

80%

(16 of 20) experienced hearing improvements per pure tone audiometry assessments at a threshold of ≤ 70 dB HL at 24 weeks

70%

(14 of 20) demonstrated an auditory brainstem response (ABR) at ≤ 90 decibels at 24 weeks

42%

of all participants (5 of 12) achieved normal hearing that included whispers (≤ 25 dB HL) at 48 weeks



"[Travis] didn't know his name. He couldn't hear me tell him how much I love him. And now with Regeneron and this amazing surgery, he can listen to music. And he loves it. And he loves to dance."

- SIERRA SMITH

mother of Travis Smith, a two-year-old treated with Otarmeni

As a part of our commitment to expanding access to our groundbreaking medicines for patients, Regeneron entered an agreement with the United States government to offer Otarmeni for free to eligible patients in the U.S.

Regeneron pipeline targets large opportunities across therapeutic categories

Ophthalmology

Cemdisiran (C5 siRNA) ± Pozelimab (C5 Ab)*	Geographic atrophy
Undisclosed Target	Glaucoma
Undisclosed Target	Thyroid Eye Disease, Graves



\$15B+

Immunology & Inflammation

IL-13	Type 2 Indications
IL-4	Type 2 Indications
IL-4xIL-13 bispecific§	Type 2 Indications
REGN1908-1909 (FelD1)	Cat Allergy
REGN5713-5715 (BetV1)	Birch Allergy
Multiple Agents§	Food Allergy
Itepekimab (IL-33)†	COPD, CRSwNP
Undisclosed Target	Lupus, Sjogren's, PBC, others



\$50B+

Oncology & Heme-Onc

Lynozoyic (BCMAxCD3)	Multiple myeloma
Fianlimab (LAG3) + Libtayo (PD-1)	1L metastatic melanoma, adjuvant melanoma
Ordspono (CD20xCD3)	Lymphoma
Ubamatamab (MUC16xCD3)	Ovarian Cancer



\$60B+

THERAPEUTIC AREAS



\$15B+

Hematology

Cemdisiran (C5 siRNA) + Pozelimab (C5 Ab)*	Paroxysmal nocturnal hemoglobinuria
REGN7508^{CAT} (FXI)	Post-TKR VTE, Cancer VTE, PICC-associated thrombosis, SPAF, PAD
REGN9933^{A2} (FXI)	PICC-associated thrombosis, SPAF, PAD



\$50B+

Cardiovascular & Metabolic Diseases

Olatorepatide (GIP/GLP-1)	Obesity, T2D
Olatorepatide (GIP/GLP-1) + Praluent (PCSK9)	Obesity, T2D with dyslipidemia
GLP-1 + Trevogrumab (GDF8)	Muscle Sparing
Nex-z (TTR)†	ATTR
MASH siRNA* (CIDEb, PNPLA3, HSD17B13)	MASH




\$15B+

Neurology & Rare Diseases

Cemdisiran (C5 siRNA)*	gMG
Garetosmab (Actinin A)	FOP
SNCA siRNA*	Parkinson's Disease
SOD1 siRNA*	ALS
MAPT (Tau) siRNA*	Alzheimer's Disease
HTT siRNA*	Huntington's Disease

Regeneron approved and investigational medicines across a diverse set of diseases



Deploying capital to maximize long-term value creation

Disciplined capital allocation approach laying the foundation for Regeneron's next wave of innovation

Internal Investment



Investing in world-class R&D capabilities and infrastructure to support sustainable growth

~\$6B Non-GAAP R&D* spend expected in 2026

\$9B+ committed to U.S. manufacturing and R&D infrastructure expansion over the coming years

Business Development



Leveraging external innovation to complement internal R&D

Expand through **complementary opportunities** across early and late development stages

- Collaboration with Alnylam, including in-licensing of **cemdisiran (C5 siRNA)**
- **GLP-1/GIP** in-licensed for obesity franchise expansion[†]
- Global collaborations for investigative **gene editing** therapies with Intellia, Mammoth and Tessaera
- Collaboration with Telix on next generation radiopharmaceutical therapies

Return Capital to Shareholders



Rewarding shareholders through opportunistic share repurchases and dividends

Repurchased **~\$800 million** of shares in Q1 2026

Board of Directors authorized new **\$3B** share repurchase program in April; **~\$3.4B** available for repurchases in the aggregate[‡]

Most recent quarterly dividend paid on June 4, 2026 (**\$0.94 / share**)

Our responsible approach:

“DO WELL BY DOING GOOD”



Responding to the 2026 Ebola outbreak: Regeneron's science and preparedness in action

Regeneron's Inmazeb® was the first treatment approved by the U.S. FDA for *Zaire Ebolavirus*; has been used in 100s of patients

- Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity *in vitro* against Bundibugyo ebolavirus
- Maftivimab has been recommended by the WHO for prioritized evaluation in clinical trials during the current Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda
- Inmazeb supply is already on the ground in the DRC for immediate use, and Regeneron is preparing maftivimab for potential use in upcoming clinical trials

Regeneron has a track record of rapidly delivering important medical solutions during times of global health crisis, such as the COVID-19 pandemic and multiple Ebola outbreaks.



In September 2025, Regeneron donated 500 doses of Inmazeb to the WHO for use in countries at greatest risk of Ebola outbreaks



REGENERON[®]

GAAP to Non-GAAP Reconciliations

REGENERON PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited)
(In millions, except per share data)

	Three Months Ended March 31,	
	2026	2025
GAAP R&D	\$ 1,543.5	\$ 1,327.4
Stock-based compensation expense	(135.1)	(141.0)
Non-GAAP R&D	\$ 1,408.4	\$ 1,186.4
GAAP SG&A	\$ 647.7	\$ 633.0
Stock-based compensation expense	(89.2)	(95.2)
Litigation settlements	5.0	—
Other costs	(3.2)	(0.8)
Non-GAAP SG&A	\$ 560.3	\$ 537.0
GAAP COGS	\$ 373.4	\$ 265.5
Stock-based compensation expense	(33.1)	(19.5)
Intangible asset amortization expense	(39.4)	(28.7)
Temporary manufacturing interruption-related costs	(91.9)	—
Non-GAAP COGS	\$ 209.0	\$ 217.3
GAAP COCM	\$ 296.0	\$ 198.8
Temporary manufacturing interruption-related costs	(14.8)	—
Non-GAAP COCM	\$ 281.2	\$ 198.8
GAAP other income (expense), net	\$ 188.3	\$ 313.3
Gains on marketable and other securities, net	(25.0)	(139.9)
Non-GAAP other income (expense), net	\$ 163.3	\$ 173.4
GAAP net income	\$ 727.2	\$ 808.7
Total of GAAP to non-GAAP reconciling items above	376.7	145.3
Income tax effect of GAAP to non-GAAP reconciling items	(67.5)	(25.6)
Income tax expense: Shortfall from stock-based compensation	3.1	—
Non-GAAP net income	\$ 1,039.5	\$ 928.4
Non-GAAP net income per share - basic	\$ 10.00	\$ 8.70
Non-GAAP net income per share - diluted	\$ 9.47	\$ 8.22
Shares used in calculating:		
Non-GAAP net income per share - basic	104.0	106.7
Non-GAAP net income per share - diluted	109.8	113.0

Q1 2026 vs Q1 2025

Total Dupixent Net Product Sales - Outside the U.S.	
% growth as reported	28%
% growth at constant currency	20%
Total Dupixent Net Product Sales - Global	
% growth as reported	33%
% growth at constant currency	31%
Total Libtayo Net Product Sales - Outside the U.S.	
% growth as reported	64%
% growth at constant currency	48%
Total Libtayo Net Product Sales - Global	
% growth as reported	54%
% growth at constant currency	48%
Total EYLEA & EYLEA 8mg Net Product Sales - Outside the U.S.	
% growth as reported	(15%)
% growth at constant currency	(21%)

(\$ in millions)	Projected Range for 2026	
	Low	High
GAAP R&D	\$ 6,450	\$ 6,680
Stock-based compensation expense	550	580
Non-GAAP R&D	\$ 5,900	\$ 6,100

Abbreviations and Definitions

Abbreviation	Definition
AAV	Adeno-associated virus
ABR	Auditory Brainstem Response
AD	Atopic dermatitis
AFRS	Allergic fungal rhinosinusitis
ALS	Amyotrophic lateral sclerosis
ATTR	Transthyretin amyloidosis
BCC	Basal cell carcinoma
BCMA	B-cell maturation antigen
BLA	Biologics License Application
BP	Bullous pemphigoid
C5	Complement component 5
CAR-T	Chimeric antigen receptor T-cell
CFB	Complement Factor B
COPD	Chronic obstructive pulmonary disease
CR	Complete Response
CRSwNP	Chronic sinusitis with nasal polyposis
CSCC	Cutaneous squamous cell carcinoma
CSU	Chronic spontaneous urticaria
EC	European Commission
EGFR	Epidermal growth factor receptor
ENT	Ear, Nose & Throat doctors (otolaryngologists)
FDA	Food and Drug Administration
FIH	First in human
FOP	Fibrodysplasia Ossificans Progressiva
GIP	Gastric inhibitory polypeptide

Abbreviation	Definition
GLP-1	Glucagon-like peptide 1
gMG	Generalized myasthenia gravis
HL	Hearing Loss
H&N	Head and Neck
HTT	Huntington
IL	Interleukin
IgE	Immunoglobulin-E
I/O	Immuno-oncology
I&I	Immunology & Inflammation
LAG-3	Lymphocyte-activation gene 3
LEPR	Leptin receptor
LDL/LDL-C	Low-Density Lipoprotein / Low-Density Lipoprotein-Cholesterol
MAPT	Microtubule-associated protein tau
MASH	Metabolic Dysfunction-Associated Steatohepatitis
MUC16	Mucin 16
NCCN	National Comprehensive Cancer Network
NDA	New Drug Application
NSCLC	Non-small cell lung cancer
STEM	Science, Technology, Engineering, and Mathematics
PAD	Peripheral artery disease
PBC	Primary Biliary Cholangitis
PD-1/PD-(L)1	Programmed cell death protein/(ligand) 1
PDUFA	Prescription Drug User Fee Act
PNH	Paroxysmal nocturnal hemoglobinuria
POC	Proof-of-concept
PSMA	Prostate-specific
REMS	Risk Evaluation and Mitigation Strategy
r/r	Relapsed/Refractory

Abbreviation	Definition
R&D	Research & Development
RVO	Retinal vein occlusion
siRNA	Small interfering RNA
SPAF	Stroke Prevention in Atrial Fibrillation
T2D	Type 2 diabetes
VEGF	Vascular endothelial growth factor
VTE	Venous thromboembolism
YoY	Year-over-Year
WHO	World Health Organization